Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Cash & Current Investments readings, the most recent being $185.8 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 118.76% to $185.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $185.8 million, a 118.76% increase, with the full-year FY2025 number at $188.9 million, up 399.1% from a year prior.
  • Cash & Current Investments hit $185.8 million in Q4 2025 for Enanta Pharmaceuticals, down from $188.9 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $386.6 million in Q2 2023 to a low of $36.4 million in Q2 2024.
  • Median Cash & Current Investments over the past 5 years was $246.6 million (2021), compared with a mean of $233.4 million.
  • Biggest five-year swings in Cash & Current Investments: tumbled 90.59% in 2024 and later soared 461.01% in 2025.
  • Enanta Pharmaceuticals' Cash & Current Investments stood at $259.1 million in 2021, then dropped by 17.21% to $214.5 million in 2022, then surged by 57.2% to $337.2 million in 2023, then crashed by 74.8% to $85.0 million in 2024, then skyrocketed by 118.76% to $185.8 million in 2025.
  • The last three reported values for Cash & Current Investments were $185.8 million (Q4 2025), $188.9 million (Q3 2025), and $204.1 million (Q2 2025) per Business Quant data.